Skip to Content

'
Zhimin (James) Lu, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Neuro-Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

  • Signal transduction

  • Cancer metabolism

  • Tumorigenesis and progression

Precise regulation of cellular signaling is important for cell growth and differentiation, cell metabolism, apoptosis, and organ and tissue development; dysregulation of cell signaling can lead to the development of cancer. Cancer develops as a result of alterations in normal intracellular and intercellular signaling. Protein kinases play important roles in transducing, amplifying, and integrating cellular signals and, thus, play a key role in the development of cancer. In my laboratory, we study tumorigenesis and tumor progression, focusing on the following research topics:

  1. Understanding how cancer advances by altering cell metabolism. Tumorigenesis is often associated with altered carbohydrate metabolism, characterized by increased glucose uptake and elevated lactic acid production under aerobic conditions, which was first recognized by Otto Warburg 85 years ago. However, the exact molecular mechanisms underlying the altered glycolysis in cancer cells remain unclear. Notably, it was recently reported that tumor cells exclusively express pyruvate kinase isozyme type M2 (PKM2), which regulates the rate-limiting final step of glycolysis. Depletion of PKM2 in human cancer cells reverses the Warburg effect and inhibits tumor formation. We have elucidated that PKM2 has dual roles that are essential for tumorigenesis: regulating the Warburg effect and gene transcription for cell proliferation by binding to and transactivating Tyr-phosphorylated -catenin. The coordinated control of metabolism and proliferation by PKM2 is essential for tumor progression (Nature, 2011).
  2. Understanding how cancer cells migrate, invade, and metastasize by altering cell–cell contract and cell–extracellular matrix (ECM) interaction and by facilitating intercellular crosstalk between tumor cells and neighboring cells. We have found that activation of growth factor receptor kinases, such as the epidermal growth factor receptor (EGFR), promotes tumorigenesis and tumor cell invasion and metastasis by disrupting cell–cell contact. This process is mediated by caveolae-dependent endocytosis of E-cadherin and snail-regulated transcriptional repression of E-cadherin (Cancer Cell, 4:499-515, 2003). In addition, EGFR activation initiates intracellular crosstalk between EGFR- and Wnt-induced signaling pathways and promotes beta-catenin transactivation by releasing beta-catenin from cell-adhesion complex. This regulation is accomplished by AKT-phosphorylated beta-catenin at S552, which facilities disruption of the E-cadherin–beta-catenin interaction, and ERK-CK2 protein kinase cascade-dependent phosphorylation of alpha-catenin at S641, which promotes abrogation of the interaction between beta-catenin and alpha-catenin (Molecular Cell, 36:547-59, 2009). Furthermore, the activation of EGFR or its downstream Ras will reduce focal adhesion by dephosphorylation and inhibition of the focal adhesion kinase (FAK), which is mediated by ERK-dependent FAK phosphorylation at S910. FAK phosphorylation at S910 results in PIN1-dependent prolyl isomerization of FAK and subsequent recruitment of PTP-PEST for FAK dephosphorylation at Y397 (Molecular Cell, 35:11-25, 2009). The combination of disrupted cell–cell contact, reduced focal adhesion, and accelerated turnover of focal contacts promotes tumor cell migration, invasion, and metastasis.
  3. Understanding how cancer progresses by promoting cell survival. Cancer cells promote cell survival by upregulation of antiapoptotic molecules. In our research on the regulation of cell survival and apoptosis, we have found that c-Jun, a major transcription factor in the activating protein 1 (AP-1) family, is downregulated in response to stress stimulation and chemotherapeutic drug treatment. The downregulation of c-Jun, which is regulated by MEKK1 (functioning as a MAP kinase kinase kinase and an E3 ligase)-mediated ubiquitination (Molecular Cell, 9:945-956, 2002) and HDAC3-dependent transcriptional repression, promotes cell apoptosis (Molecular Cell, 25:219-232, 2007).

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Department of Neuro-Oncology - Research
Unit Number: 1002
Houston, TX 77030
Room Number: BSRB S5.8116B
Email: zhiminlu@mdanderson.org

Education & Training

Degree-Granting Education

1998 The Graduate School and University Center, City University of New York, New York, NY, PHD, Molecular, Cellular and Developmental Biology
1986 Taishan Medical College, Shandong, China, MD, Medicine

Postgraduate Training

1/1999-9/2003 Research Fellowship, Department of Molecular and Cell Biology, Cancer Center Designated by the National Cancer Institute, The Salk Institute for Biological Studies, La Jolla, CA, Tony Hunter
9/1986-1/1992 Physician/Oncologist, Qingdao Hospital, Qingdao, China

Experience/Service

Other Appointments/Responsibilities

Research Associate/Postdoctoral Fellow, The Salk Institute for Biological Studies, La Jolla, CA, 1/1999-9/2003
Physician and Oncologist, Qingdao Hospital, Qingdao, NY, China, 9/1986-1/1992

Institutional Committee Activities

Member, Brain Tumor Center (BTC) Research Seminar Series Committee, 2010-present
Member, The Odyssey Program Committee, 2009-present
Member, The Cancer Biology Program International Student Admission Committee of Graduate School of Biomedical Sciences (GSBS), 2009-present
Reviewer, Internal Review for CPRIT (Cancer Prevention and Research Institute of Texas) Applications, 2009
Ad Hoc Reviewer, The Center for Targeted Therapeutics (CTT) Research Fund, 2008
Ad Hoc Reviewer, Bridge Fund, 2007
Member, Brain Tumor Center (BTC) Laboratory Sciences Committee, 2006-present

Honors and Awards

2011 The Faculty Scholar Award, The University of Texas MD Anderson Cancer Center
2009-2013 American Cancer Society Research Scholar, American Cancer Society
2008 Peter Steck Memorial Young Investigator Award, Pediatric Brain Tumor Foundation
2005 Wang Kuan-Cheng Foundation Award, Chinese Academy of Science
2000 California Breast Cancer Research Program Postdoctoral Fellowship, California Breast Cancer Research Program

Selected Publications

Peer-Reviewed Original Research Articles

1. Liu DX, Qian D, Wang B, Yang JM, Lu Z. p300-Dependent ATF5 Acetylation Is Essential for Egr-1 Gene Activation and Cell Proliferation and Survival. Mol Cell Biol 31(18):3906-16, 9/2011. PMID: 21791614.
2. Chiu WT, Lee HT, Huang FJ, Aldape KD, Yao J, Steeg PS, Chou CY, Lu Z, Xie K, Huang S. Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res 71(14):4932-43, 7/2011. PMID: 21622714.
3. Ji H, Wang J, Fang B, Fang X, Lu Z. a-catenin inhibits glioma cell migration, invasion, and proliferation by suppression of ß-catenin transactivation. J Neurooncol. 103(3):445-51, 2011. PMID: 20872274.
4. Yang W, Xia X, Zheng Y, Liang J, Huang W, Gao X, Aldape K, Lu Z. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 480(7375):118-22, 2011 - Outstanding research publication award at MDAnderson; Highlighted in MDAnderson News Release, also Highlighted in SciBX,, 2011. PMID: 22056988.
5. Zheng Y, Yang W, Xia Y, Hawke D, Liu DX, Lu Z. Ras-induced and ERK1/2 Phosphorylation-Dependent Isomerization of PTP-PEST by PIN1 Promotes FAK Dephosphorylation by PTP-PEST. Mol Cell Biol 31(21):4258-69, 2011. PMID: 21876001.
6. Ding Z, Liang J, Li J, Lu Y, Ariyaratna V, Lu Z, Davies MA, Westwick JK, Mills GB. Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. PLoS One 5(3):e9910, 2010. PMCID: PMC2845649.
7. Lu Z, and Hunter T. Ubiquitination and proteasomal degradation of p27kip1, p21cip1, and p57kip2. Cell Cycle 12:2342-2352, 2010.
8. Ji H, Wang J, Nika H, Hawke D, Keezer S, Ge Q, Fang B, Fang X, Fang D, Litchfield DW, Aldape K, Lu Z. EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell 36(4):547-59 (Selected as the feature article by Mol Cell and highlighted in Cell and M.D. Anderson News Release), 11/2009. PMCID: PMC2784926.
9. Zheng Y, Lu Z. Paradoxical roles of FAK in tumor cell migration and metastasis. Cell Cycle 8(21):3474-9, 11/2009. PMID: 19829089.
10. Chen H, Xia Y, Fang D, Hawke D, Lu Z. Caspase-10-mediated heat shock protein 90 beta cleavage promotes UVB irradiation-induced cell apoptosis. Mol Cell Biol 29(13):3657-64, 7/2009. PMCID: PMC2698753.
11. Lu Z, Hunter T. Degradation of activated protein kinases by ubiquitination. Ann Rev Biochem 78:435-75, 7/2009. PMCID: PMC2776765.
12. Zheng Y, Xia Y, Hawke D, Halle M, Tremblay M, Gao X, Zhou X, Aldape K, Cobb M, Xie K, He J, and Lu Z. FAK phosphorylation by ERK primes Ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. Mol Cell 35(1):11-25 (Highlighted in Mol Cell and Faculty of 1000 Biology), 7/2009. PMCID: PMC2715139.
13. Liu S, Fang X, Hall H, Yu S, Smith D, Lu Z, Fang D, Liu J, Stephens C, Woodgett J, and Mills G. Homozygous deletion of glycogen synthase kinase 3 beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proc Natl Acad Sci USA 105(13):5248-53, 4/2008. PMCID: PMC2278194.
14. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu Z. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 282(15):11221-229, 4/2007. PMCID: PMC1850976.
15. Xia Y, Wang J, Liu TJ, Yung WK, Hunter T, Lu Z. c-Jun downregulation by HDAC3-dependent transcriptional repression promotes osmotic stress-induced cell apoptosis. (Selected as the feature article by Mol Cell and received MDACC Nycomed GmbH Outstanding Research Publication Award in 2007). Mol Cell 25(2):219-32, 1/2007. PMCID: PMC1829326.
16. Xia Y, Wang J, Xu S, Johnson GL, Hunter T, Lu Z. MEKK1 mediates the ubiquitination and degradation of c-Jun in response to osmotic stress. Mol Cell Biol 27(2):510-517, 1/2007. PMID: 17101801.
17. Lu Z, Xu S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 58(11):621-31, 11/2006. PMID: 17085381.
18. Ya X, Lu Z. The ubiquitination-mediated degradation of epidermal growth factor receptor. (Review) . Acta Acad Med Sin 27(1):120-27, 2/2005. PMID: 15782507.
19. Lu Z, Hunter T. Wnt-independent beta-catenin transactivation in tumor development. Cell Cycle 3(5):571-3, 5/2004. PMID: 15107603.
20. Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell 4(6):499-515 (Highlighted in: Nat Rev Cancer 2004; 4:90-91; Nature Signaling & Update/The signaling gateway 2004, and Faculty of 1000 Biology), 12/2003. PMID: 14706341 (Highlighted in: Nat Rev Cancer 2004; 4:90-91; Nature Signaling & Update/The signaling gateway 2004, and Faculty of 1000 Biology).
21. Lu Z, Xu S, Joazeiro C, Cobb MH, Hunter T. The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2. Mol Cell 9(5):945-56, (Highlighted in: Nat Rev Mol Cell Biol 2002;3:473; Nature-Signaling Update/the signaling gateway, 2002; and Faculty of 1000 Biology), 5/2002. PMID: 12049732.
22. Lu Z, Jiang G, Blume-Jensen P, Hunter T. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 21(12):4016-31, 6/2001. PMID: 11359909.
23. Zhong M*, Lu Z*, Abbas T, Hornia A, Chatakondu K, Barile N, Kaplan P, Foster DA (*equal contribution). Novel tumor-promoting property of tamoxifen. Cell Growth Differ 12(4):187-92, 4/2001. PMID: 11331247.
24. Goi T, Shipitsin M, Lu Z, Foster DA, Klinz SG, Feig LA. An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity. EMBO J 19(4):623-30, 2/2000. PMID: 10675331.
25. Lu Z, Hornia A, Joseph T, Sukezane T, Frankel P, Zhong M, Bychenok S, Xu L, Feig LA, Foster DA. Phospholipase D and RalA cooperate with the epidermal growth factor receptor to transform 3Y1 rat fibroblasts. Mol Cell Biol 20(2):462-7, 2000. PMID: 10611224.
26. Hornia A*, Lu Z*, Sukezane T, Zhong M, Joseph T, Frankel P, Foster DA (*equal contribution). Antagonistic effects of protein kinase C alpha and delta on both transformation and phospholipase D activity mediated by the epidermal growth factor receptor. Mol Cell Biol 19:7672-80, 11/1999.
27. Lu Z, Liu D, Hornia A, Devonish W, Pagano M, Foster DA. Activation of protein kinase C triggers its ubiquitination and degradation. Mol Cell Biol 18(2):839-45, 2/1998. PMID: 9447980.
28. Lu Z, Hornia A, Jiang YW, Zang Q, Ohno S, Foster DA. Tumor promotion by depleting cells of protein kinase C delta. Mol Cell Biol 17(6):3418-28, 6/1997. PMID: 9154841.
29. Jiang H, Luo JQ, Urano T, Frankel P, Lu Z, Foster DA, Feig LA. Involvement of Ral GTPase in v-Src-induced phospholipase D activation. Nature 378(6555):409-12, 11/1995. PMID: 7477381.

Book Chapters

1. Lu Z, Hunter T. MEKK1: Dual function as a protein kinase and a ubiquitin protein ligase. In: Protein Degradation: The Ubiquitin-Proteasome System. 2. Ed(s) RJ Mayer, A Ciechanover, M Rechsteiner. WILEY-VCH Verlag GmbH & Co. KGaA: Germany, 79-89, 2006. PMID: 3-527-31130-0.
2. Lu Z. Activation of Wnt Signaling in Tumor Development. In: Current Topics in Human Genetics: Studies in Complex Diseases. Ed(s) HW Deng, H Shen, YL Liu, H Hu. World Scientific Publishing Co: Singapore, 809-32, 2007. PMID: 981-270-472-8.

Grant & Contract Support

Title: Deciphering the mechanisms of EFGR-regulated Warburg effect during tumorigenesis
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 1/1/2011 - 12/31/2013
 
Title: The role of b-catenin regulation by PKM2 in tumor development
Funding Source: Global Academic Programs' Sister Institution Network Fund (SINF)
Role: Principal Investigator
Duration: 2011 - 2013
 
Title: The "SPORE in Brain Cancer" Developmental Research Program
Funding Source: Special Program of Research Excellence (SPORE)
Role: Principal Investigator
Duration: 9/1/2010 - 8/31/2011
 
Title: Deciphering metabolic cooperation between EGFR and NF-κB pathways in tumor development
Funding Source: The University of Texas M. D. Anderson Cancer Center, Institutional Research Grant (IRG)
Role: Principal Investigator
Duration: 1/2010 - 12/2011
 
Title: The mechanism of beta-catenin transactivation induced by ErbB2 activation in medulloblastoma
Funding Source: Pediatric Brain Tumor Foundation (PBTF)
Role: Principal Investigator
Duration: 1/1/2005 - 1/1/2006
 
Title: The Role of Beta-catenin in EGFR-related Tumor Development
Funding Source: The Charlotte Geyer Foundation
Role: Principal Investigator
Duration: 8/1/2004 - 7/31/2005
 
Title: The Mechanism of EGF-induced beta-catenin Transactovatopm
Funding Source: The University of Texas M. D. Anderson Cancer Center, Institutional Research Grant (IRG)
Role: Principal Investigator
Duration: 1/1/2004 - 12/31/2006
 
Title: Tamoxifen-induced endometrial cell transformation
Funding Source: California Breast Cancer Research Program, University of California, Office of the President
Role: Principal Investigator
Duration: 8/1/2000 - 7/31/2002
 
Title: Tamoxifen-induced endometrial cell transformation
Funding Source: The Salk Institute
Role: Principal Investigator
Duration: 1999
 
Title: Regulation of nuclear Beta-catenin in EGFR-promoted tumor development, (percentile: 8%)
Funding Source: NIH/NCI
Role: Principal Investigator

Last updated: 12/6/2011